Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)
CAPS Rating:
A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.
RSS Headlines
Fool UK
Recs
disruptive technology that could be a substantial winner in the near term